Venetoclax and azacitidine therapy in acute myeloid leukemia patients with severe renal impairment

Affiliations

• ¹ Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan.
• ² Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan.
• ³ Department of Hematology/Oncology and Transfusion and Hemapheresis Center, Kurashiki Central Hospital, Kurashiki, Okayama, Japan.
• ⁴ Department of Hematology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan.
• ⁵ Department of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Osaka, Japan.
• ⁶ The Center for Hematological Diseases, Takeda General Hospital, Kyoto, Kyoto, Japan.
• ⁷ Department of Hematology, Hyogo Prefectural Tamba Medical Center, Tamba, Hyogo, Japan.
• ⁸ Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Kyoto, Japan.
• ⁹ Division of Hematopoietic Disease Control, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.